Arrowhead Pharmaceuticals (United States)

Recent papers from Arrowhead Pharmaceuticals (United States)

1. Impact of GLP-1 Receptor Agonist Use on Triglyceride Reduction with PlozasiranCanadian Journal of Diabetes · 2026
2. Plozasiran for Severe Hypertriglyceridemia and Risk of PancreatitisNew England Journal of Medicine · 2026
3. A Case Report of a Pregnant Woman With Familial Chylomicronemia Syndrome Treated With Plozasiran, a Small Interfering Rna Against Apoc3.Atherosclerosis · 2026
4. Pharmacokinetics, Pharmacodynamics, and Safety of Plozasiran in Subjects With Renal or Hepatic ImpairmentAtherosclerosis · 2026
5. Effect of Targeting ApoC-III With Plozasiran on Lipoprotein Particle Size and Number in HypertriglyceridemiaJournal of the American College of Cardiology · 2025
6. Skin Cancer Recognition and Education Among Community Health Workers in Southern New MexicoInternational Journal of Environmental Research and Public Health · 2026
7. Longer-Term Efficacy and Safety of Zodasiran in Patients with Mixed HyperlipidaemiaEuropean Journal of Preventive Cardiology · 2026
8. Endothelial KLF4 depletion drives age-related neurovascular dysfunction and neuropsychiatric impairmentProceedings of the National Academy of Sciences · 2026
9. Stereoselective Phosphorylation of d-Ribose as a Driver of Life’s HomochiralityLife · 2026
10. Population Pharmacodynamic Modeling of Plozasiran for Treatment of Familial Chylomicronemia SyndromeThe Journal of Clinical Pharmacology · 2026
11. 434: Predictive Value of Teg With Platelet Mapping on Hematoma Expansion in Spontaneous IchCritical Care Medicine · 2026
12. Experimental and Numerical Modeling of Liposome Congregation in Meteorite Craters of Early EarthLife · 2026
13. Early detection and intervention in dermatomyositis: current evidence and clinical implicationsClinical Rheumatology · 2026
14. A randomized, placebo-controlled phase 3 study of plozasiran in patients with familial chylomicronemia syndrome: PALISADE - 1 year open label extensionEuropean Heart Journal · 2025
15. Safety and efficacy of zodasiran, a hepatic sirna targeting angptl3, in mixed hyperlipidemia patients: 2 year open label extension (OLE) results from ARCHES-2European Heart Journal · 2025
16. Safety and Effectiveness of the Santreva™-ATK Endovascular Revascularization Catheter in the RESTOR-1 Peripheral CTO Crossing Pivotal StudyThe American Journal of Cardiology · 2026
17. Safety, pharmacokinetics and pharmacodynamics of Plozasiran in Chinese healthy volunteersCardiovascular Diabetology · 2025
18. Virological Insights from ARC-520 siRNA and Entecavir Treated Chronically HBV-Infected Patients and ChimpanzeesMicroorganisms · 2025
19. A Novel Conservation Genomic Strategy: Selection for the Probability of Offspring HeterozygosityAnimals · 2025
20. Smile to Like: Effects of Facial Expression-Based Evaluation on Media Engagement and Emotional Self-AwarenessACM Transactions on Applied Perception · 2025